Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Trial offers hope for koala chlamydia vaccine
koala
“Chlamydia is one of the major threats to our koala populations".

Scientists report world's first successful trial involving wild koalas

Australian scientists have carried out the world's first successful trial of a vaccine against chlamydia in koala bears.

Microbiologists from the University of Sunshine Coast (USC) in Queensland have spent five years leading the research. In previous studies, the team trialled the vaccine on captive koalas, but for the past year they have been testing its effects in wild animals.

Sixty koalas were captured from their natural habitat in the Moreton Bay region north of Brisbane. Half were vaccinated, while the remaining thirty were left unvaccinated as a control group. Each koala was fitted with a radio tag for monitoring purposes.

Professor Timms, who led the research, said the results were "very promising". The vaccinated koalas showed good immune responses and lower levels of chlamydia infection than the unvaccinated group.

“This large trial has confirmed that the vaccine is safe to give to not only captive koalas, but also koalas in the wild,” he said.

However, the trial will continue for at least another year. The team hope to show the vaccine's positive impacts on disease and female reproductivity, as well as infection.

Professor Timms also hopes to assess the vaccine's impact on other koala populations facing the threat of chlamydial disease, but this will require further funding.

“We feel compelled to start using this vaccine more broadly, especially when we know that it is safe and has some definite positive benefit to the animals,” he said.

“But a project of this size and cost requires a large team of people, including veterinarians and field teams, in addition to the laboratory aspects.”

The Queensland Government provided funding of $358,000 to the trial. State environment minister Andrew Powell said: “Chlamydia is one of the major threats to our koala populations and that’s why we’ve invested significant funds into combating this disease.

“Among other things, chlamydia in koalas can lead to blindness and infertility, so it’s clear why we need to support research that can stem these conditions.”
A special fund has been set up for those wishing to offer donations to the project:
http://www.usc.edu.au/community/giving-to-usc/giving-opportunities/koala-research-project

To watch a video of the researchers discussing their work, visit: http://www.youtube.com/watch?v=yrfbHfO76e0&feature=youtu.be

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.